$CLDX, Price Target in View Celldex Therapeutic
Post# of 23071
Posted On: 03/30/2016 1:49:32 PM
$CLDX,
Price Target in View Celldex Therapeutics, Inc. (NASDAQ:CLDX)
0
By Small Cap Contributor on March 30, 2016 Stock Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus price target of $8.75 on shares. Out of all the covering analysts polled by Zacks Research that were included for this target, the analyst with the highest price target sees the stock hitting $24. The lowest analyst target price has shares going to $4. These targets may differ between covering analysts. Analysts have the ability to use resistance and support levels to help evaluate a stock target price. Zacks research also uses calculated recommendations from covering Wall Street analysts. These recommendations are on a scale provided by Zacks Research. Based on information provided from various analysts, Zacks Research shows shares of Celldex Therapeutics, Inc. having an ABR of 2. This number is based on a ratings scale where the ratings fall between a 1 and a 5. Following this scale, a 1 would represent a Strong Buy while a 5 would indicate a Strong Sell.
We can also take a look at some company earnings per share or EPS information. Earnings per share is the segment of profit for a company that is allocated to every outstanding share of a company’s common stock. Earnings per share numbers can serve as an indicator for the profitability of a certain company. EPS is widely considered to be one of the most important factors when evaluating the price of a share. A Zacks consensus currently shows Street analysts projecting the company to post per share earnings of $-0.34. For the period ending 2015-12-31, Celldex Therapeutics, Inc. reported actual EPS of $-0.33. This number was $0.01 away from analyst predictions, providing a surprise factor of 2.94%. The company is expected to next release earnings on or around 2016-05-04.
Celldex Therapeutics, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with Ma
Price Target in View Celldex Therapeutics, Inc. (NASDAQ:CLDX)
0
By Small Cap Contributor on March 30, 2016 Stock Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given a consensus price target of $8.75 on shares. Out of all the covering analysts polled by Zacks Research that were included for this target, the analyst with the highest price target sees the stock hitting $24. The lowest analyst target price has shares going to $4. These targets may differ between covering analysts. Analysts have the ability to use resistance and support levels to help evaluate a stock target price. Zacks research also uses calculated recommendations from covering Wall Street analysts. These recommendations are on a scale provided by Zacks Research. Based on information provided from various analysts, Zacks Research shows shares of Celldex Therapeutics, Inc. having an ABR of 2. This number is based on a ratings scale where the ratings fall between a 1 and a 5. Following this scale, a 1 would represent a Strong Buy while a 5 would indicate a Strong Sell.
We can also take a look at some company earnings per share or EPS information. Earnings per share is the segment of profit for a company that is allocated to every outstanding share of a company’s common stock. Earnings per share numbers can serve as an indicator for the profitability of a certain company. EPS is widely considered to be one of the most important factors when evaluating the price of a share. A Zacks consensus currently shows Street analysts projecting the company to post per share earnings of $-0.34. For the period ending 2015-12-31, Celldex Therapeutics, Inc. reported actual EPS of $-0.33. This number was $0.01 away from analyst predictions, providing a surprise factor of 2.94%. The company is expected to next release earnings on or around 2016-05-04.
Celldex Therapeutics, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with Ma
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'